Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: HER2-positive Breast Cancer|Stage III Ovarian Epithelial Cancer|Stage III Ovarian Germ Cell Tumor|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer|Stage IV Ovarian Epithelial Cancer|Stage IV Ovarian Germ Cell Tumor
Interventions: BIOLOGICAL: pNGVL3-hICD vaccine|BIOLOGICAL: sargramostim|OTHER: flow cytometry|OTHER: immunologic technique|OTHER: immunoenzyme technique|GENETIC: protein expression analysis|PROCEDURE: biopsy
Sponsor: University of Washington
Collaborators: National Cancer Institute (NCI)